Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus as First-line Treatment in Advanced GI or Pancreatic Neuroendocrine Tumors
NCT01648465Phase 2Terminated
- Sponsor
- HeCOG
- Start
- Aug 2012
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in gastrointestinal neuroendocrine tumor, Pancreatic neuroendocrine tumor (PanNET), sponsored by HeCOG. Started Aug 2012; status: terminated.
02
Drugs
everolimus
03
Conditions
gastrointestinal neuroendocrine tumorPancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT01648465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01648465.